Droxidopa_product_DataBase

Bioactivity

Droxidopa(L-DOPS) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder)[1][2][3][4].

In Vivo

Droxidopa (200 mg/kg;i.p.) alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats[2].Droxidopa (10, 20 mg/kg; i.p.) significantly increases the paw withdrawal latency and inhibits mechanical hypersensitivity to thermal stimulation in 6-OHDA-lesioned rats at the 5th week after surgery[3]. Animal Model:

Name

Droxidopa

CAS

23651-95-8

Formula

C9H11NO5

Molar Mass

213.19

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Horacio Kaufmann, et al. Droxidopa for neurogenic orthostatic hypotension. Neurology, 2014; 83(4). [2]. Dela Peña I, et al. Droxidopa alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats. Eur J Pharmacol. 2021 Feb 5;892:173826. [3]. Cao LF, et al. Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease. Neural Plast. 2016;2016:6383240. [4]. Kaufmann H. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res. 2008 Mar;18 Suppl 1:19-24.

PeptideDB

Droxidopa

CAS: 23651-95-8 F: C9H11NO5 W: 213.19